DeepaSSubramaniamMD

Oncology • Washington, DC

Genitourinary Oncology, Hematologic Oncology, Neuro-Oncology, Thoracic Cancer

Associate Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Subramaniam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Subramaniam's full profile

Already have an account?

Office
3800 Reservoir Road Nw
Podium A Lombardi
Washington, DC 20007
Phone+1 202-444-2223

Fax+1 202-444-7009

Summary

Post by RFHDC.

Race for Hope DC - CureBrainTumors.org

Dr. Deepa Subramaniam is a neuro-oncologist at the Georgetown Lombardi Comprehensive Cancer Center. She is also a team captain in the Race for Hope-DC

Education & Training

MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
Providence HospitalResidency, Internal Medicine, 1999 - 2002
University of WashingtonMS, 1995 - 1997
Kilpauk Medical CollegeClass of 1993

Certifications & Licensure

DC State Medical License 2004 - 2020

Awards, Honors, & Recognition

Top Fundraising Team Award Race for Hope - DC, 2017
Triumph of the Spirit Award for Excellence in Brain Tumor Care The Rabbi Joseph Weinberg Foundation, 2014
Teaching Excellence Award Georgetown University, 2013
Hattie McDaniels Health Award Seven Pearls Foundation, 2011
Join now to see all

Clinical Trials

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Start of enrollment: 2016 Dec 20
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

34 citations
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic
Journal for Immunotherapy of Cancer. 2022-08-01
10 citations
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
Chul Kim, Stephen V. Liu, Jennifer Crawford, Tisdrey Torres, Vincent Chen
Frontiers in Oncology. 2021-09-08
64 citations
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
David A. Reardon, Tae Min Kim, Jean-Sebastien Frenel, Matteo Simonelli, Juanita Lopez
Cancer. 2021-05-15

Authored Content

CME Course Non -Small Cell Lung Cancer5/9/2016

Press Mentions

Increased Infection Rates Associated with Tetracycline Therapy Given for Epidermal Growth Factor Receptor Inhibitor (EGFRI)-Associated Acneiform Eruption: A Retrospective Study of Data from Two Cancer CentersJuly 4th, 2019
OncLive® Presents the Latest State of the Science Summit™ on Advances in Lung Cancer ManagementOctober 29th, 2018
No Increase in Brain Tumors Seen from Cell PhonesDecember 3rd, 2009